Diabetes, Obesity and Metabolism

Endothelial progenitor cells for the treatment of diabetic vasculopathy: panacea or Pandora's box?
pp. 353-366(14)
Authors: Liew,; McDermott,; Barry,; O'Brien,

The effect of thiazolidinediones on adiponectin serum level: a meta-analysis
pp. 367-375(9)
Authors: Riera-Guardia,; Rothenbacher,

Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes
pp. 376-386(11)
Authors: Rosenstock,; Sankoh,; List,

Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial
pp. 387-399(13)
Authors: Davies,; Lavalle-González,; Storms,; Gomis,

Non-oxidative glucose disposal is reduced in type 2 diabetes, but can be restored by aerobic exercise
pp. 400-407(8)
Authors: Yokoyama,; Mori,; Emoto,; Araki,; Teramura,; Mochizuki,; Tashiro,; Motozuka,; Inoue,; Nishizawa,

Beta cells in type 2 diabetes - a crucial contribution to pathogenesis
pp. 408-420(13)
Author: Maedler, Kathrin

Effects of insulin vs. glibenclamide in recently diagnosed patients with type 2 diabetes: a 4-year follow-up
pp. 421-429(9)
Authors: Alvarsson,; Sundkvist,; Lager,; Berntorp,; Fernqvist-Forbes,; Steen,; Örn,; Holberg,; Kirksæther,; Grill,

National Cholesterol Education Program and International Diabetes Federation definitions of metabolic syndrome in the prediction of diabetes. Results from the FIrenze-Bagno A Ripoli study
pp. 430-435(6)
Authors: Mannucci,; Monami,; Cresci,; Pala,; Bardini,; Petracca,; Dicembrini,; Pasqua,; Buiatti,; Rotella,

Response to Pokharna and Kanna: Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes
pp. 436-437(2)

News and Views
pp. 438-440(3)
Author: Idris, Iskandar